Table 1.
Comparison of baseline characteristics between normal weight and overweight patients with COVID-19.
| Variables * | BMI 18.5–24.9 (n = 113) | BMI > 24.9 (n = 250) | p-Value |
|---|---|---|---|
| Background data | |||
| Age | 0.407 | ||
| 18–40 years | 21 (18.6%) | 33 (13.2%) | |
| 40–65 years | 54 (47.8%) | 129 (51.6%) | |
| >65 years | 38 (33.6%) | 88 (35.2%) | |
| Gender (men) | 62 (54.9%) | 137 (54.8%) | 0.990 |
| Area of residence (urban) | 68 (60.2%) | 143 (57.2%) | 0.594 |
| Occupation (employed) | 66 (58.4%) | 124 (49.6%) | 0.119 |
| Smoking | 43 (38.1%) | 129 (51.6%) | 0.016 |
| Alcohol use disorder | 9 (8.0%) | 17 (6.8%) | 0.690 |
| Comorbidities | |||
| Malignancy | 7 (6.2%) | 26 (10.4%) | 0.196 |
| Chronic lung disease | 11 (9.7%) | 39 (15.6%) | 0.133 |
| Cardiovascular disease | 51 (45.1%) | 114 (45.6%) | 0.934 |
| Cerebrovascular disease | 8 (7.1%) | 33 (13.2%) | 0.088 |
| Diabetes mellitus | 14 (12.4%) | 56 (22.4%) | 0.025 |
| Autoimmune disease | 3 (2.7%) | 12 (4.8%) | 0.341 |
| Chronic kidney disease | 4 (3.5%) | 14 (5.6%) | 0.402 |
| Digestive and liver disease | 11 (9.7%) | 51 (20.4%) | 0.012 |
| COVID-19 treatment | |||
| Antivirals | 103 (91.2%) | 239 (95.6%) | 0.092 |
| Corticosteroids | 99 (87.6%) | 211 (84.4%) | 0.422 |
| Antibiotics | 87 (77.0%) | 214 (85.6%) | 0.043 |
| Anticoagulants | 75 (66.4%) | 183 (73.2%) | 0.184 |
| Immune modulators | 28 (24.8%) | 83 (33.2%) | 0.106 |
* Data reported as n (%) and calculated using Chi-square test and Fisher’s exact unless specified differently; BMI—Body Mass Index.